A six-month systems toxicology inhalation/cessation study in ApoE−/− mice to investigate cardiovascular and respiratory exposure effects of modified risk tobacco products, CHTP 1.2 and THS 2.2, compared with conventional cigarettes
Year: 2019
Type: article
Abstract: Smoking is one of the major modifiable risk factors in the development and progression of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). Modified-risk tobacco products (MRTP) are being developed to provide substitute products for smokers who are unable or unwilling to quit, to lessen the smoking-related health risks. In this study, the ApoE -/- mouse model was used to investigate the impact of cigarette smoke (CS) from the reference cigarette 3R4F, or aerosol from two potential MRTPs based on the heat-not-burn principle, carbon heated tobacco product 1.2 (CHTP1.2) and tobacco heating system 2.2 (THS 2.2), on the cardiorespiratory system over a 6-month period. In addition, cessation or switching to CHTP1.2 after 3 months of CS exposure was assessed. A systems toxicology approach combining physiology, histology and molecular measurements was used to evaluate the impact of MRTP aerosols in comparison to CS. CHTP1.2 and THS2.2 aerosols, compared with CS, demonstrated lower impact on the cardiorespiratory system, including low to absent lung inflammation and emphysematous changes, and reduced atherosclerotic plaque formation. Molecular analyses confirmed the lower engagement of pathological mechanisms by MRTP aerosols than CS. Both cessation and switching to CHTP1.2 reduced the observed CS effects to almost sham exposure levels.
Source: Food and Chemical Toxicology
Authors: Blaine Phillips, Justyna Szostak, Bjoern Titz, Walter K. Schlage, Emmanuel Guedj, Patrice Leroy, Gregory Vuillaume, Florian Martin, Ansgar Buettner, Ashraf Elamin, Alain Sewer, Nicolas Sierro, Mohamed Amin Choukrallah, Thomas Schneider, Nikolai V. Ivanov, Charles Teng, Ching Keong Tung, Wei Ting Lim, Ying Shan Yeo, Patrick Vanscheeuwijck, Manuel C. Peitsch, Julia Hoeng
Institution: Philip Morris International (Switzerland)
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,950
Funder: Philip Morris International
OpenAlex ID: W2911337652
